Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib in Advanced HR+/HER2+ Breast Cancer
NCT07706179Phase 2Not yet recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Nov 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in breast cancer, sponsored by University of Wisconsin–Madison. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
alisertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07706179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07706179.